ClinicalTrials.Veeva

Menu
M

Medical Research Partners | Ammon, ID

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3841136
Eloralintide
LY3549492
LY573144
Lasmiditan
Tirzepatide
Galcanezumab
Macupatide
LY3502970
LY3305677

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 16 total trials

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3532226
Drug: LY3841136

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Active, not recruiting
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Active, not recruiting
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 t...

Begins enrollment in 2 months
Diabetes Mellitus, Type 2
Drug: Orforglipron
Drug: Dulaglutide

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition...

Enrolling
Weight Gain
Obesity
Drug: Tirzepatide
Drug: Placebo

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and sa...

Enrolling
Overweight
Obesity
Drug: Macupatide
Drug: Eloralintide

The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (202...

Active, not recruiting
COVID-19
SARS-COV-2 Infection
Biological: BNT162b2 (2025/2026 formulation)

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germ...

Enrolling
Pneumococcal Disease
Biological: PG4
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralint...

Enrolling
Overweight or Obesity
Osteoarthritis
Drug: Placebo
Drug: Eloralintide

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germ...

Enrolling
Pneumococcal Disease
Biological: PG4
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

Trial sponsors

Lilly logo
Pfizer logo
BioNTech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems